Summit Therapeutics (SMMT) Exchange Rate Effect (2017 - 2026)
Summit Therapeutics' (SMMT) quarterly Exchange Rate Effect came in at $1000.0 in Q2 2026, down 98.36% YoY from $61000.0 in Q2 2025, and up 105.26% on a QoQ basis from -$19000.0 in Q1 2026.
Powered by 
Analysis
Summit Therapeutics (SMMT) Exchange Rate Effect (2017 - 2026) Analysis & Trends
Summit Therapeutics (SMMT) has 10 years of Exchange Rate Effect data on file, last reported at $1000.0 in Q2 2026.
- Quarterly Exchange Rate Effect fell 98.36% year-over-year to $1000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$15000.0 (down 114.29% YoY) and the FY2025 annual result came in at $102000.0, up 666.67% from the prior year.
- Exchange Rate Effect rose to $1000.0 in Q2 2026, from -$19000.0 in the prior quarter.
- In the past five years, Exchange Rate Effect ranged from a high of $1.4 million in Q4 2022 to a low of -$1.8 million in Q3 2022.
- A 5-year average of -$17611.1 and a median of $6500.0 in 2024 frame the typical range for Exchange Rate Effect.
- The widest YoY moves for Exchange Rate Effect: up 428.16% in 2022, down 621.74% in 2022.
- Tracing SMMT's Exchange Rate Effect over 5 years: stood at $1.4 million in 2022, then plunged by 80.22% to $272000.0 in 2023, then tumbled by 139.71% to -$108000.0 in 2024, then surged by 82.41% to -$19000.0 in 2025, then jumped by 105.26% to $1000.0 in 2026.
- The last three Exchange Rate Effect figures came in at $1000.0 (Q2 2026), -$19000.0 (Q1 2026), and -$19000.0 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -3.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -300,000.00 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -2.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.84 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -2.45 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -287,000.00 |
| 10 | Summit Therapeutics | 13.67 Bn | 12.98 Bn | - | 1,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1,000.00 |
| Mar 31, 2026 | -19,000.00 |
| Dec 31, 2025 | -19,000.00 |
| Sep 30, 2025 | 22,000.00 |
| Jun 30, 2025 | 61,000.00 |
| Mar 31, 2025 | 38,000.00 |
| Dec 31, 2024 | -108,000.00 |
| Sep 30, 2024 | 114,000.00 |
| Jun 30, 2024 | 12,000.00 |
| Mar 31, 2024 | -36,000.00 |
| Dec 31, 2023 | 272,000.00 |
| Sep 30, 2023 | -170,000.00 |
| Jun 30, 2023 | 293,000.00 |
| Mar 31, 2023 | 444,000.00 |
| Dec 31, 2022 | 1.38 Mn |
| Sep 30, 2022 | -1.83 Mn |
| Jun 30, 2022 | -605,000.00 |
| Mar 31, 2022 | -166,000.00 |
| Dec 31, 2021 | -419,000.00 |
| Sep 30, 2021 | -253,000.00 |